Prof José Manuel Barroso, Chair of the Gavi Board, and Dr Sania Nishtar, CEO of Gavi since 18 March 2024, reflect on the driving forces of progress in 2023 and plans for 2024.

In the time it takes you to read this article, six people’s lives will have been saved by Gavi-supported vaccines. Here are seven statistics on Gavi’s impact in 2023.

Gavi’s 2022 Annual Progress Report highlights the impact of investment in immunisation across 57 Gavi-supported countries.

Prof José Manuel Barroso, Chair of the Gavi Board, and Gavi CEO (ad int) David Marlow on achievements and challenges in 2022, and priorities and goals for 2023.

Gavi’s 2021 Annual Progress Report, released today, is a record in numbers of another difficult pandemic year – a year of alarming setbacks, and a year of hard-won gains.

Prof José Manuel Barroso, Chair of the Gavi Board, reflects on the achievements of lower-income countries during the pandemic.

Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance, looks back on the first year of Gavi 5.0

Even with the adversities and challenges of the COVID-19 pandemic through 2020, Gavi maintained unyielding focus on leaving no one behind.

Despite the havoc wrought by the COVID-19 pandemic on health systems worldwide, governments’ work to bring immunisation programmes back on track is paying off.

A growing number of countries are transitioning out of Gavi support. Here’s how we help them sustainably finance and manage their vaccine programmes over the long term.

Here’s how Gavi helps lower-income countries get the new vaccines and products they need to address urgent threats to public health – from cholera and COVID-19, to Ebola and pneumonia.

The Vaccine Alliance has been working hard in recent years to build greater resilience in supply chains, an effort that is starting to show results.

Over 50% more children were immunised in Gavi countries in 2019 than in 2000, yet 10.6 million children continue to miss out entirely on basic vaccinations. Here’s why reaching these children and setting them on the pathway to full immunisation…

Building and maintaining demand for immunisation is an integral part of Gavi’s work to increase coverage and equity. Here’s an insight into how we have achieved this.

One of the vital components to Gavi’s capital structure is the International Finance Facility for Immunisation (IFFIm). A powerful and award-winning financial tool launched in 2006, IFFIm issues Vaccine Bonds on the capital markets against long-…

Gavi’s long-term approach to developing healthy markets for critical vaccines has led to greater stability and security, providing countries with the confidence that supplies will be available to meet their demand.

In 2019, a higher share of Gavi-supported countries than ever before met their co-financing obligations on time, thanks to strong political commitment.

In 2019, countries delivered more than 230 million routine vaccinations, a record number, supported by unprecedented levels of health system funding from Gavi to support immunisation and protect the most vulnerable children. Here is what Gavi did…

Throughout the 2016–2020 strategic period, the Vaccine Alliance has worked with countries to improve data quality. From GIS to SMS, new tech and tools aim to reach more people with life-saving immunisation.

To bring countries on a trajectory towards financial sustainability, and to empower them to take ownership
of their vaccination programmes, Gavi has pioneered an approach to co-financing and transition.

Gavi's partnership with telecoms provider Orange and the Ministry of Health overcomes barriers to childhood immunisation through tailored, tested technology.

The benefits of immunisation extend beyond preventing childhood deaths. Vaccines are also a vital tool in the fights against cancer, outbreaks and antimicrobial resistance.

The goal of our market shaping work is to help ensure vaccine markets work better for lower-income countries. We want the maximum number of people to receive the life-saving and health-protecting benefits of immunisation.

After transitioning out of Gavi support in 2017, the Republic of Moldova is mobilising champions and advocates to strengthen vaccine confidence – which is crucial to the success and sustainability of immunisation programmes.

Typhoid fever is increasingly resistant to the main antibiotics used to treat it. Gavi is supporting a new vaccine to help control this deadly disease – and fight antimicrobial resistance.

Snapshots from DRC, India and Zambia illustrate country ownership and progress in the fights against Ebola, polio and HPV.

Supporting health systems is essential for Gavi’s work to improve immunisation coverage and equity.

When disaster strikes a country, the impact on people’s health can be immense and long-lasting. As the effects of climate change are felt around the world through rising temperatures and sea levels, natural disasters are increasingly frequent and…

Vaccines are the best tools yet invented to prevent child deaths and protect people’s health. Gavi funding for access to vaccines has protected a generation of children growing up in lower-income countries. Gavi funds twin approaches to…

Gavi’s CEO provides an overview of its flagship publication, launched today.